Abstract
Background: Biological drugs represent highly effective but costly treatments for chronic immunemediated inflammatory diseases posing substantial burden on health care budgets. Introduction of biosimilars since 2013 has brought forward the potential of market competition, and as a societal benefit, the hope of increased access at a lower cost.
Objective: We aim to provide a descriptive review on economic aspects and market changes related to the introduction of biosimilar drugs.
Method: Our focus is on chronic immune-mediated inflammatory conditions in rheumatology, gastroenterology and dermatology. Based on available literature data, we discuss the determinants of access to biological treatment, summarize the available health economic evidences with special focus on cost-utility and budget impact analyses. Market penetration of biosimilars and their overall impact on biological markets are analyzed.
Results: Biosimilar markets are country specific due to differences in the regulatory and reimbursement systems. Cost-utility analyses suggest, that given the lower price of biosimilars, formerly established biological treatment sequence practices and the eligibility criteria for biological treatment deserve reconsideration. Budget impact analyses forecasted significant budget savings in various diagnoses and countries, providing opportunity for the treatment of more patients.
Conclusion: Biosimilars may contribute to better patient-access and provide savings to governments. To increase their acceptability, further clinical evidences and real world experiences are needed, as well as education of physicians and patients. The high biosimilar penetration rates in Norway, Denmark and Poland suggest that policies which support interchanging from the reference product may be important drivers of biosimilar uptake.
Keywords: Biosimilar pharmaceuticals, access, autoimmune diseases, costs, budget impact, economics.
Current Pharmaceutical Design
Title:The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases
Volume: 23 Issue: 44
Author(s): Marta Pentek*, Zsombor Zrubka and Laszlo Gulacsi
Affiliation:
- Department of Health Economics, Faculty of Economics, Corvinus University of Budapest, Budapest,Hungary
Keywords: Biosimilar pharmaceuticals, access, autoimmune diseases, costs, budget impact, economics.
Abstract: Background: Biological drugs represent highly effective but costly treatments for chronic immunemediated inflammatory diseases posing substantial burden on health care budgets. Introduction of biosimilars since 2013 has brought forward the potential of market competition, and as a societal benefit, the hope of increased access at a lower cost.
Objective: We aim to provide a descriptive review on economic aspects and market changes related to the introduction of biosimilar drugs.
Method: Our focus is on chronic immune-mediated inflammatory conditions in rheumatology, gastroenterology and dermatology. Based on available literature data, we discuss the determinants of access to biological treatment, summarize the available health economic evidences with special focus on cost-utility and budget impact analyses. Market penetration of biosimilars and their overall impact on biological markets are analyzed.
Results: Biosimilar markets are country specific due to differences in the regulatory and reimbursement systems. Cost-utility analyses suggest, that given the lower price of biosimilars, formerly established biological treatment sequence practices and the eligibility criteria for biological treatment deserve reconsideration. Budget impact analyses forecasted significant budget savings in various diagnoses and countries, providing opportunity for the treatment of more patients.
Conclusion: Biosimilars may contribute to better patient-access and provide savings to governments. To increase their acceptability, further clinical evidences and real world experiences are needed, as well as education of physicians and patients. The high biosimilar penetration rates in Norway, Denmark and Poland suggest that policies which support interchanging from the reference product may be important drivers of biosimilar uptake.
Export Options
About this article
Cite this article as:
Pentek Marta *, Zrubka Zsombor and Gulacsi Laszlo , The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases, Current Pharmaceutical Design 2017; 23 (44) . https://dx.doi.org/10.2174/1381612824666171129193708
DOI https://dx.doi.org/10.2174/1381612824666171129193708 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design A Dilemma of Functional Genomics: Count the Chickens or Study their Eggs ?
Current Genomics Gene Therapy as a Novel Pharmaceutical Intervention for Stroke
Current Pharmaceutical Design Melatonin in Antinociception: Its Therapeutic Applications
Current Neuropharmacology The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors
Current Pharmaceutical Biotechnology Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics The Natural Flavonoid Naringenin Inhibits the Cell Growth of Wilms Tumor in Children by Suppressing TLR4/NF-κB Signaling
Anti-Cancer Agents in Medicinal Chemistry Intrinsic Activity at Adenosine A1 Receptors: Partial and Inverse Agonism
Current Pharmaceutical Design Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk
Protein & Peptide Letters Immune Responses to Lentiviral Vectors
Current Gene Therapy Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology In Silico Prediction Models for Blood-Brain Barrier Permeation
Current Medicinal Chemistry Plant-food-derived Bioactives in Managing Hypertension: From Current Findings to Upcoming Effective Pharmacotherapies
Current Topics in Medicinal Chemistry Intravesical Drug Delivery into the Bladder to Treat Cancers
Current Drug Delivery Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry Synthesis of Apoptotic New Quinazolinone-Based Compound and Identification of its Underlying Mitochondrial Signalling Pathway in Breast Cancer Cells
Current Pharmaceutical Design Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry Modulatory Role of Nitric Oxide/cGMP System in Endothelin-1-Induced Signaling Responses in Vascular Smooth Muscle Cells
Current Cardiology Reviews